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OBJECTIVES: To compare 12-month psychiatric-related hospi-
talization pre and post-RLAI therapy and clinical outcomes in
early (<5-years) versus late (°Y´5-years) diagnosis outpatients
with schizophrenia from e-STAR in Spain (SP), Australia (AU),
and Belgium (BE). METHODS: E-STAR is a secure, web-based,
international, long-term observational study of patients with
schizophrenia who commence RLAI treatment. Data are col-
lected both retrospectively and prospectively and include hospi-
talisations and clinical outcomes that were evaluated using the
Clinical Global Impression Severity Scale (CGI-S) and Global
Assessment of Functioning Scale (GAF). RESULTS: Overall, 714
patients (SP = 393, AU = 249, BE = 72) were included. Twenty-
two percent were classiﬁed as early diagnosis. Average time since
diagnosis was 2 and 15.9 years in the early and late diagnosis
group, respectively. Patients in the early diagnosis group were
signiﬁcantly younger than those in the late diagnosis group (32.2
vs. 41.7, p < 0.001). Both groups experienced a signiﬁcant
decrease in the number of hospitalizations per patient in the 12-
month post versus the 12-month pre-RLAI period (early = 0.77
to 0.36, p < 0.001; late = 0.54 to 0.43, p = 0.004). Reduction in
hospitalization rates per patient from the pre and post-RLAI
period was signiﬁcantly greater in the early diagnosis group
(early = −0.4, late = −0.11, p = 0.006). The average length of
stay (in days) decreased for both groups but it was only statisti-
cally signiﬁcant in the early diagnosis group (early = 21.2 to 12.4,
p = 0.041; late = 15.6 to 13.6, p = 0.40). Both groups experi-
enced signiﬁcant improvements in GAF and CGI-S scores.
However, the early diagnosis group experienced greater improve-
ments in GAF and signiﬁcantly greater improvements in CGI
(GAF: early = +14.1, late = +12.5, p = 0.30; CGI: early = −1.04,
late = −0.76, p = 0.017). CONCLUSION: This interim analysis
suggests that treatment with RLAI result in better outcomes in
patients with schizophrenia who have been diagnosed for less
than ﬁve-years than those diagnosed for ﬁve or more years.
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OBJECTIVES: Cox proportional hazards models comparing
patient outcomes achieved across alternative drug therapies may
be sensitivity to alternative speciﬁcations for censoring of the
data prior to an event. Three criteria are used in drug studies:
duration of therapy; time to a change in therapy; and end of
available data. METHODS: California Medicaid data for
1994–2003 were used to identify 165,013 episodes of antipsy-
chotic drug therapy initiated during CY2000–2002 by patients
with schizophrenia. Cox models were estimated separately for
acute or a psychiatric hospital admissions controlling for patient
demographics, diagnostic proﬁle, prescription drug proﬁle and
prior health care use. Four types of treatment episodes were
deﬁned based on discontinuation of therapy: patients restarting
or switching drugs after a break in therapy >15 days and patients
switching or augmenting a pre-existing antipsychotic regimen
with no break in treatment. Clozapine or ziprasidone episodes
were excluded due to small sample size. Patients initiating treat-
ment using a typical antipsychotic (TAP) were combined into a
single comparison group. RESULTS: Patients using atypical
antipsychotics achieved longer duration of therapy than TAP
patients for all episode types, creating a longer period of risk
exposure for an event in Cox models that censor data based on
duration of therapy. The Cox models for all episode types com-
bined did ﬁnd that the hazard ratios for all three atypical antipsy-
chotics were reduced relative to TAP when duration of therapy
was dropped as a censoring criterion. However, changes in the
estimated hazard ratios were small and the results from separate
analyses by episode type were not always consistent with the
aggregate model results. Patients switching therapies were con-
sistently found to be at higher risk for hospitalization than
patients restarting a drug used in their previous treatment
attempt. CONCLUSION: Cox hazard ratios are sensitive to cen-
soring speciﬁcations based on duration of therapy.
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OBJECTIVES: To assess switching of atypical and typical
antipsychotics among stable and unstable patients and the rela-
tionship between switching and hospitalization. METHODS: We
used data from the ﬁrst year of a large (N = 2327), 3-year non-
interventional observational study of schizophrenia patients in
the U.S, conducted between 7/1997 and 9/2003. Participants
with at least one prescription for any antipsychotic were included
in this analysis. Participants were deﬁned as “stable” if they had
PANSS total scores below 70 at enrollment and no psychiatric
hospitalization, psychiatric emergency services, suicide attempt,
or arrest in the 1–6 months prior to enrollment. All other par-
ticipants were deemed “unstable.” Systematic medical record
abstraction provided antipsychotic prescription information.
The stable and unstable patient groups were compared on
antipsychotic switching rates (switch from the antipsychotic used
at enrollment) and on antipsychotic augmentation. Group com-
parisons were performed using t-tests for continuous variables
and Chi-square tests for categorical variables. RESULTS: Of
2158 participants, 59.6% were deemed unstable and 40.4%
were considered stable. Unstable patients were more likely to
experience switching and augmentation of antipsychotics.
Typical antipsychotics were more likely to be used as augmen-
tors (58.7%, p < 0.001), whereas atypical antipsychotics, espe-
cially olanzapine, were more likely the medications to be
switched to (61.9%, p < 0.001). A signiﬁcantly higher propor-
tion of switchers (44.6%) than non-switchers (17.9%, p < 0.001)
were hospitalized for psychiatric purposes during the 1-year
observation period. Among switchers who were hospitalized at
any time during the 1-year period, 52.4% switched medication
during hospitalization, 29.8% switched prior to hospitalization,
and 17.8% switched post hospitalization. CONCLUSION:
Switching of antipsychotics appears to be signiﬁcantly associated
with unstable, more severe illness proﬁle and with psychiatric
hospitalizations. Atypical antipsychotics are more likely the med-
ications to be switched to. Finding an effective treatment option
